Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

NCT02652455 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Melanoma (Skin)
Skin Cancer

Interventions

DRUG: Nivolumab
PROCEDURE: Surgery to Remove Tumor for Growth of TIL
DRUG: CD137
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: TIL Infusion
DRUG: Interleukin-2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]
[object Object]